UNICHEMLAB
Unichem Laboratories share price & financials
- Price
- ₹444.3
- Market cap
- ₹3.8k Cr
- Sector
- Healthcare
- Calls analysed
- 5
Unichem Labs. Q3 FY17
Revenue (Q3 FY17) ₹360 cr (+16% YoY); EBITDA (Q3 FY17) ₹44 cr (+30% YoY); PAT (Q3 FY17) ₹26 cr (+30% YoY). Q3 FY17 Revenue stood at Rs. 360 Crores, marking a 16% year-on-year growth.
Read the full call →What Unichem Laboratories Limited does
Unichem Laboratories Limited is an Indian pharmaceutical manufacturer, incorporated in 1962, that became a subsidiary of Ipca Laboratories Limited. It operates active pharmaceutical ingredient (API) plants at Roha and Kolhapur (Maharashtra) and Pithampur (Madhya Pradesh), and formulation manufacturing facilities at Goa, Ghaziabad, Baddi and Sikkim carrying USFDA, MHRA, ANVISA and TGA approvals. It earns by supplying APIs and formulations to parent Ipca on a contract-manufacturing basis and by selling its own US-market formulations through its wholly-owned US marketing subsidiary, Unichem Pharmaceuticals (USA) Inc., which also markets a portfolio of Ipca-origin, US-ANDA-approved generics. The company previously ran a large India branded-formulations business; that domestic footprint has shrunk sharply since the Ipca ownership change, with the business now weighted toward API/formulation supply and export/US generics.
Segments
- API (Active Pharmaceutical Ingredients)
- Formulations
- Corporate structure
- Subsidiary of Ipca Laboratories Limited, a global pharmaceutical company
- API manufacturing plants
- Roha and Kolhapur (Maharashtra), Pithampur (Madhya Pradesh)
- Formulation manufacturing plants
- Goa, Ghaziabad, Baddi (HP) and Sikkim
- Plant regulatory approvals
- USFDA, MHRA, ANVISA and TGA-approved formulation plants (Goa and Ghaziabad)
- US marketing subsidiary
- Unichem Pharmaceuticals (USA) Inc., established 2004, markets Unichem-manufactured products in the US
- US ANDA product portfolio marketed via Unichem USA
- ~20 Ipca-origin formulations with approved US ANDAs, ~25 more filings in process
Guidance record · Q3 FY17
what the last two calls moved 11 tracked 3 delivered 5 missed 3 open- Domestic Business Growth delivered said Q3 FY16 Promised: robust double-digit growth Q3 FY17: 9M FY17 growth clocked in at 'around 12% plus', meeting the double-digit target.
- US Business Growth Rate missed said Q3 FY16 Promised: maintain growth of over 35% Q3 FY17: 9M FY17 growth was 23%, which is within the revised 20-30% range but a clear miss on the original 'over 35%' target.
- Operating Margin Expansion at risk said Q4 FY16 Promised: 100-150 BPS expansion in the coming year Q3 FY17: YTD EBITDA margin expansion was only 4 BPS (11.96% vs 11.92% LY). While Q3 YoY showed 133 BPS improvement, the full-year target is at risk.
All 11 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 20.1%, net profit up 510.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 507 | 533 | 587 | 527 | 579 +14% | 521 −2% | 575 −2% | 633 +20% |
| EBITDA | 55 | 86 | 84 | 22 | 66 +20% | 45 −48% | 48 −43% | 70 +218% |
| Net profit | 25 | 58 | 53 | -10 | -12 −148% | 264 +355% | 11 −79% | 41 +510% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +8.8% 1Y
1Y: ₹495.85 on 10 Sept 2025 → ₹539.7. High ₹650.6 (9 Jul 2026), low ₹284.05 (27 Mar 2026).
Financials, as filed
Revenue grew 17.9% a year over 3 years, FY23 to FY26. Operating margin widened to 8.2%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹1.3k Cr | ₹1.7k Cr | ₹2.1k Cr | ₹2.2k Cr |
| Operating profit | ₹-46 Cr | ₹93 Cr | ₹265 Cr | ₹181 Cr |
| Operating margin | -3.4% | 5.4% | 12.6% | 8.2% |
| Interest | ₹18 Cr | ₹24 Cr | ₹21 Cr | ₹31 Cr |
| Depreciation | ₹114 Cr | ₹117 Cr | ₹125 Cr | ₹125 Cr |
| Net profit | ₹-202 Cr | ₹-81 Cr | ₹138 Cr | ₹253 Cr |
| Net margin | -15.0% | -4.7% | 6.5% | 11.5% |
| Cash from operations | ₹-85 Cr | ₹14 Cr | ₹-7 Cr | ₹4 Cr |
| Free cash flow | ₹-123 Cr | ₹0 Cr | ₹-142 Cr | ₹163 Cr |
| ROCE | -5.0% | 0.0% | 6.0% | 4.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr |
| Reserves | ₹2.5k Cr | ₹2.6k Cr | ₹2.4k Cr | ₹2.4k Cr | ₹2.4k Cr | ₹2.7k Cr |
| Borrowings | ₹119 Cr | ₹349 Cr | ₹314 Cr | ₹248 Cr | ₹502 Cr | ₹500 Cr |
| Other liabilities | ₹436 Cr | ₹351 Cr | ₹444 Cr | ₹589 Cr | ₹619 Cr | ₹489 Cr |
| Total liabilities | ₹3.1k Cr | ₹3.3k Cr | ₹3.2k Cr | ₹3.3k Cr | ₹3.6k Cr | ₹3.7k Cr |
| Fixed assets | ₹884 Cr | ₹990 Cr | ₹1.3k Cr | ₹1.3k Cr | ₹1.2k Cr | ₹1.2k Cr |
| Capital work in progress | ₹568 Cr | ₹494 Cr | ₹147 Cr | ₹123 Cr | ₹79 Cr | ₹100 Cr |
| Investments | ₹392 Cr | ₹264 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹1.3k Cr | ₹1.6k Cr | ₹1.8k Cr | ₹1.9k Cr | ₹2.2k Cr | ₹2.4k Cr |
| Total assets | ₹3.1k Cr | ₹3.3k Cr | ₹3.2k Cr | ₹3.3k Cr | ₹3.6k Cr | ₹3.7k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public added +0.53 pp while DIIs trimmed −0.46 pp. The shareholder count grew 10% to 25,347.
- Promoters
- 70.2%
- FIIs
- 0.9%
- DIIs
- 10.5%
- Public
- 18.4%
Since Jun 2025
- Public +0.53 pp
- DIIs −0.46 pp
- FIIs −0.08 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 70.2%, FIIs 0.8%, DIIs 10.0%, Public 18.9%.Dec '23: Promoters 70.2%, FIIs 0.8%, DIIs 10.5%, Public 18.5%.Mar '24: Promoters 70.2%, FIIs 0.9%, DIIs 11.3%, Public 17.6%.Jun '24: Promoters 70.2%, FIIs 0.9%, DIIs 11.6%, Public 17.3%.Sep '24: Promoters 70.2%, FIIs 0.9%, DIIs 11.7%, Public 17.2%.Dec '24: Promoters 70.2%, FIIs 1.1%, DIIs 11.6%, Public 17.1%.Mar '25: Promoters 70.2%, FIIs 1.0%, DIIs 11.3%, Public 17.5%.Jun '25: Promoters 70.2%, FIIs 1.0%, DIIs 10.9%, Public 17.9%.Sep '25: Promoters 70.2%, FIIs 1.0%, DIIs 10.7%, Public 18.0%.Dec '25: Promoters 70.2%, FIIs 1.0%, DIIs 10.7%, Public 18.1%.Mar '26: Promoters 70.2%, FIIs 1.0%, DIIs 10.6%, Public 18.1%.Jun '26: Promoters 70.2%, FIIs 0.9%, DIIs 10.5%, Public 18.4%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- DSP Healthcare Fund Mutual fund +0.35 pp 1.56% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Unichem Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Ipca Laboratories Limited | 52.67% | unchanged |
| Dr. Prakash Amrut Mody | 12.78% | unchanged |
| HDFC Small Cap Fund Mutual fund | 7.75% | unchanged |
| Anita Prakash Mody | 1.88% | unchanged |
| DSP Healthcare Fund Mutual fund | 1.56% | +0.35 pp |
| Suparna Prakash Mody | 1.35% | unchanged |
| Supriya Prakash Mody | 1.35% | unchanged |
| Investor Education And Protection Fund Authority Ministry Of Corporate Affairs | 1.04% | unchanged |
| Dr. Prakash Amrut Mody - Suparna Mody Trust (Promoter Trust ) | 0.07% | unchanged |
| Dr. Prakash Amrut Mody - Shwetambari Mody Trust (Promoter Trust) | 0.06% | unchanged |
| Dr. Prakash Amrut Mody - Supriya Mody Trust (Promoter Trust) | 0.06% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in UNICHEMLAB
Filings to Jul 2026
0 new, 0 added, 1 trimmed, 0 sold out — net −5.00 L shares (−9.2%).
- Held by funds
- ₹255 Cr
- 1 schemes
- Biggest holder
- HDFC Small Cap Fund
- ₹255 Cr · 0.6% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| HDFC Small Cap Fund HDFC Mutual Fund | ₹255 Cr | −5.00 L | Dec '22 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Jul 2026
0 added, 1 trimmed — net −5.00 L shares (−9.2%)
- Funds are sitting on
- +31%
- vs est. average cost
- Held by funds
- ₹255 Cr
- 1 schemes · ≈ 5.8% of the company
Shares held by these funds +16%
Aug '23 49.59 L shares Jul '26
All earnings calls (5)
Read the Q3 FY17 call →Learn to analyse Unichem Laboratories Limited
Guides on how to read this kind of business and the numbers that matter.